用于骨髓瘤的CD38靶向锆-去铁胺-达雷妥尤单抗PET成像：免疫PET对临床治疗的影响 - Suppr

Suppr

超能文献

CD38-Targeted Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care.

作者信息

Ulaner Gary A, Lewis Jason, Landgren Ola

机构信息

Molecular Imaging and Therapy, Hoag Family Cancer Institute, Irvine, California;

Radiology and Translational Genomics, University of Southern California, Los Angeles, California.

出版信息

J Nucl Med. 2025 Mar 3;66(3):482. doi: 10.2967/jnumed.124.269393.

DOI:10.2967/jnumed.124.269393

PMID:39884767

Abstract

摘要

相似文献

CD38-Targeted Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care.

J Nucl Med. 2025 Mar 3;66(3):482. doi: 10.2967/jnumed.124.269393.

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.

Radiology. 2020 Jun;295(3):606-615. doi: 10.1148/radiol.2020192621. Epub 2020 Apr 7.

Preclinical Development of CD38-Targeted [Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma.

J Nucl Med. 2018 Feb;59(2):216-222. doi: 10.2967/jnumed.117.196063. Epub 2017 Oct 12.

Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas.

ACS Omega. 2023 Apr 11;8(25):22486-22495. doi: 10.1021/acsomega.3c00624. eCollection 2023 Jun 27.

ImmunoPET imaging of CD38 in murine lymphoma models using Zr-labeled daratumumab.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1372-1381. doi: 10.1007/s00259-018-3941-3. Epub 2018 Feb 15.

CD38 as a PET Imaging Target in Lung Cancer.

Mol Pharm. 2017 Jul 3;14(7):2400-2406. doi: 10.1021/acs.molpharmaceut.7b00298. Epub 2017 Jun 8.

Application of Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody.

Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1306-1317. doi: 10.1007/s00259-023-06109-3. Epub 2023 Jan 13.

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between Zr- and Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model.

Int J Mol Sci. 2019 May 24;20(10):2564. doi: 10.3390/ijms20102564.

Therapeutic Response Monitoring with Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models.

Pharmaceutics. 2022 Jun 24;14(7):1338. doi: 10.3390/pharmaceutics14071338.

Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma.

Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):599-610. doi: 10.1007/s00259-024-06907-3. Epub 2024 Sep 11.

引用本文的文献

EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.

Nat Rev Clin Oncol. 2025 Jul 7. doi: 10.1038/s41571-025-01041-x.

Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.

Cancers (Basel). 2025 Apr 7;17(7):1247. doi: 10.3390/cancers17071247.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

CD38-Targeted Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care.

作者信息

Ulaner Gary A, Lewis Jason, Landgren Ola

机构信息

Molecular Imaging and Therapy, Hoag Family Cancer Institute, Irvine, California;

Radiology and Translational Genomics, University of Southern California, Los Angeles, California.

出版信息

J Nucl Med. 2025 Mar 3;66(3):482. doi: 10.2967/jnumed.124.269393.

DOI:10.2967/jnumed.124.269393

PMID:39884767

Abstract

摘要

相似文献

CD38-Targeted Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care.

J Nucl Med. 2025 Mar 3;66(3):482. doi: 10.2967/jnumed.124.269393.

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.

Radiology. 2020 Jun;295(3):606-615. doi: 10.1148/radiol.2020192621. Epub 2020 Apr 7.

Preclinical Development of CD38-Targeted [Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma.

J Nucl Med. 2018 Feb;59(2):216-222. doi: 10.2967/jnumed.117.196063. Epub 2017 Oct 12.

Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas.

ACS Omega. 2023 Apr 11;8(25):22486-22495. doi: 10.1021/acsomega.3c00624. eCollection 2023 Jun 27.

ImmunoPET imaging of CD38 in murine lymphoma models using Zr-labeled daratumumab.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1372-1381. doi: 10.1007/s00259-018-3941-3. Epub 2018 Feb 15.

CD38 as a PET Imaging Target in Lung Cancer.

Mol Pharm. 2017 Jul 3;14(7):2400-2406. doi: 10.1021/acs.molpharmaceut.7b00298. Epub 2017 Jun 8.

Application of Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody.

Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1306-1317. doi: 10.1007/s00259-023-06109-3. Epub 2023 Jan 13.

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between Zr- and Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model.

Int J Mol Sci. 2019 May 24;20(10):2564. doi: 10.3390/ijms20102564.

Therapeutic Response Monitoring with Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models.

Pharmaceutics. 2022 Jun 24;14(7):1338. doi: 10.3390/pharmaceutics14071338.

Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma.

Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):599-610. doi: 10.1007/s00259-024-06907-3. Epub 2024 Sep 11.

引用本文的文献

EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.

Nat Rev Clin Oncol. 2025 Jul 7. doi: 10.1038/s41571-025-01041-x.

Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.

Cancers (Basel). 2025 Apr 7;17(7):1247. doi: 10.3390/cancers17071247.